T cell and NK cells are the most promising cell types for providing treatments that could potentially offer cures to cancer and other diseases. Based on FDA guidelines, the manufacturing process for these immune cells must have high quality and controllable batch-to-batch variations in order to ensure the safety and efficacy of the "living drug."